Roche’s $7.1B bet on Roivant drug; ADCs and other #ESMO23 dispatch; Highlights from Alzheimer’s confab; Q3 pharma drama; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Between earnings…
Click here to view original post

Advertisement — Advertise with Biotech Networks